YNYi-Le Ning

Yi-Le Ning

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi-Le Ning has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Ce Sun

    The First Clinical School, Guangzhou University of Chinese Medicine Guangzhou China

    2 shared publications
  • Yu Zhang

    Department of Critical Care Medicine Shenzhen Bao'an Chinese Medicine Hospital, Guangzhou University of Chinese Medicine Shenzhen China

    2 shared publications
  • Gulizeba Muhetaer

    Shenzhen Bao'an Chinese Medicine Hospital, Guangzhou University of Chinese Medicine Shenzhen China

    1 shared publication
  • Hang Li

    Central lab, Shenzhen Bao’an Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China

    1 shared publication
  • Hua Xu

    Department of Pediatrics, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

    1 shared publication
  • Huiting Guan

    Shenzhen Bao’an Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China

    1 shared publication

Latest Publications

  • Machine Learning Interpretability to Assess the Association Between Time in Tight Range and Mortality in Cardiogenic Shock

    by Yang Jiang, Qing‐Lin Li, Yan‐Ling Huang, Yi‐Le Ning, Li‐Hua Chen, Yu Zhang, Xiang‐Hui Xu

    Background: Cardiogenic shock (CS) is a critical condition of end‐organ hypoperfusion with high mortality. Fluctuations in blood glucose (BG) levels may exacerbate cardiovascular instability in critically ill patients. Time In Tight Range (TITR), defined as the percentage of time in the target BG range of 3.9–7.8 mmol/L (70–140 mg/dL), has become an increasingly important index of glycaemic status, but its impact on mortality in CS remains unclear. Interpretable machine learning (ML) models provide transparent, quantitative and visual insights into the prognostic importance of TITR, clarifying its pivotal role in outcome prediction and providing objective evidence to support individualised glucose management. Aim: This study aimed to investigate the relationship between TITR and mortality in patients with CS, and to provide strong evidence for early intervention and personalised blood glucose management. Study Design: We conducted a retrospective multi‐cohort study to examine the association between TITR and mortality in patients with CS. The relationship between TITR and in‐hospital mortality was analysed using a restricted cubic spline (RCS) model, log‐rank test, multivariable Cox and logistic regression analyses. ML models, including XGBoost, LightGBM, CatBoost, Gradient Boosting, Support Vector Machine (SVM), Neural Network and Naive Bayes, were developed to predict mortality and compared with traditional clinical scoring systems. Model interpretability was assessed using SHapley Additive exPlanations (SHAP). Sensitivity and subgroup analyses were used to reveal the robustness of the results. Results: RCS analysis revealed an inverse (L‐shaped) association ( p < 0.001) between TITR and in‐hospital mortality in both the Medical Information Mart for Intensive Care IV (MIMIC‐IV) and the eICU Collaborative Research Database (eICU) cohorts. Kaplan–Meier survival analyses revealed the patients with TITR > 57% (High TITR group) had significantly lower in‐hospital mortality than those with TITR ≤ 57% (Low TITR group) in both cohorts. The hazard ratios (HRs) (95% confidence interval [CI]) estimated by log‐rank test were 1.72 (1.49, 1.99) and 1.49 (1.19, 1.87) in the MIMIC‐IV and eICU cohorts, respectively (both p < 0.001). Sensitivity analyses yielded consistent results, confirming the robustness of the findings. In addition, analyses of ICU mortality, 28‐day mortality (only available in the MIMIC‐IV cohort), also demonstrated a consistent pattern with the primary outcome. Based on area under curve values (AUC), ML models, including CatBoost (AUC = 0.76; 95% CI: 0.73–0.80 in MIMIC‐IV; 0.77; 95% CI: 0.72–0.83 in eICU), Gradient Boosting (AUC = 0.75; 95% CI: 0.72–0.79 and 0.74; 95% CI: 0.68–0.80) and XGBoost (AUC = 0.74; 95% CI: 0.70–0.77 and 0.76; 95% CI: 0.71–0.82), outperformed traditional scoring systems. Interpretability analysis via SHAP consistently highlighted TITR as the most influential factor in mortality prediction. Conclusions: These findings underscore the critical role of TITR in outcome prediction and demonstrate both the superiority and interpretability of ML models for risk stratification and decision support. Achieving higher TITR is associated with improved outcomes, highlighting the importance of dynamic glucose control in this population. Relevance to Clinical Practice: The findings offer evidence‐based guidance for ICU nursing interventions, highlighting TITR as a key modifiable factor for improving outcomes for patients with CS. The strong performance of ML models supports their clinical application for more accurate risk stratification, while identification of TITR as the primary mortality predictor—reinforced by transparent SHAP explanations—provides actionable insights to guide early, targeted interventions.

  • Open Access

    Vasoactive–Inotropic Score Reduction Rate Is Highly Associated With Prognosis for Critically Ill Patients With Cardiogenic Shock: Insights From the Real‐World Dynamic Data

    by Yi-Le Ning, Tian-Xiang Guan, Xiao-Li Niu, Qian-Qian Ma, Yuan-Na Zhang, Ting-Yu Peng, Li-Xiong Zeng, Hang Li, Hui-Ting Guan

    Background: In cardiogenic shock (CS), titration of both the choice and dosage of inotropes and vasopressors is crucial. The vasoactive–inotropic score (VIS) quantifies hemodynamic support, while the effect of temporal VIS change on prognosis remains unclear. This study evaluated the association between the vasoactive–inotropic score reduction rate (VRR) to measure VIS changes over time and explore its association with mortality in CS patients. Methods: We performed a retrospective observational study using two large intensive care databases (MIMIC‐IV and eICU). Adult patients with CS receiving vasoactive–inotropic agents within 24 h after ICU admission were included. VIS was calculated using the updated VIS 2020, and VRR was defined to capture the relative change in VIS over time. Patients were categorized into VIS‐decreasing and VIS‐increasing groups. The primary outcome was in‐hospital mortality; secondary outcomes were intensive care unit (ICU) and 28‐day mortality (28‐day mortality only for the MIMIC‐IV database). Associations between VRR and outcomes were examined using four models: (1) log‐rank analysis, (2) Cox model adjusted for all covariates, (3) Cox model adjusted for covariates selected by univariable analyses, and (4) Cox model adjusted for covariates selected by a random forest algorithm. Results: A total of 3170 adult CS patients were analyzed. All models in both MIMIC‐IV and eICU showed that an increasing VIS over time was consistently associated with higher in‐hospital, ICU, and 28‐day mortality compared with a decreasing VIS in the MIMIC‐IV cohort ( p < 0.001). These findings were reproduced in the external eICU cohort for ICU and in‐hospital mortality ( p < 0.001), supporting the robustness and generalizability of VRR as a prognostic indicator across heterogeneous ICUs. Conclusions: In adult CS patients, a greater reduction in VIS over time is strongly associated with lower mortality. VRR provides a simple, dynamic summary of vasoactive trajectories and may serve as a useful adjunct for risk stratification alongside other clinical and biochemical markers, although prospective validation is warranted.


  • Association between optimum blood glucose level and mortality in critically ill patients with septic shock: A real‐world time‐series data analysis

    by Gulizeba Muhetaer, Ce Sun, Qian‐Qian Ma, Yu Zhang, Jun‐Wei Zhang, Yi‐Le Ning

    Background: Sepsis remains a significant health challenge in ICU, with septic shock requiring meticulous glycaemic management due to metabolic dysregulation. Existing research highlights the detrimental effects of both hyperglycaemia and hypoglycaemia on septic patient outcomes, emphasizing the need for effective glycaemic control. Despite extensive studies, optimal glycaemic targets in septic shock patients remain contentious and unclear, necessitating further research. Aim: Our study aims to identify optimal glycaemic targets for patients in septic shock by analysing time‐series blood glucose data. Study Design: This retrospective observational study utilized the MIMIC‐IV database, encompassing ICU patients diagnosed with septic shock from 2008 to 2019. We extracted time‐series blood glucose data and applied the Stineman interpolation to achieve a standardized resolution. The primary analysis involved calculating the time‐weighted average blood glucose (TWA‐BG) and examining its relationship with 28‐day mortality using a restricted cubic spline model within a Cox regression framework. Sensitivity analyses with multiple models and subgroup analyses were used to reveal the robustness of the results. Results: From 34 677 identified septic patients, 11 375 met the inclusion criteria. The optimal TWA‐BG range, associated with the lowest 28‐day mortality risk, was determined to be 105 to 131 mg/dL. Patients within this range exhibited significantly lower mortality rates compared to those with higher or lower TWA‐BG levels. Sensitivity analyses confirmed these findings, indicating robustness across various subgroups and analytical models. Conclusions: Our findings suggest that maintaining TWA‐BG levels between 105 and 131 mg/dL minimizes the risk of 28‐day, ICU, and in‐hospital mortality in patients with septic shock. Relevance to Clinical Practice: The results provide evidence‐based guidance for ICU nursing interventions, advocating for a precise TWA‐BG range to be maintained for septic shock patients, thus potentially setting new benchmarks for glycaemic control in critical care settings.


  • Open Access

    The optimal blood glucose is significantly associated with lower mortality in critically ill patients with cardiogenic shock: an analysis revealed with time series blood glucose records

    by Ce Sun, Ji-Hong Zhou, Yan-Ling Huang, Yi-Le Ning, Xiang-Hui Xu

    Background: The optimal blood glucose (BG) level for patients with cardiogenic shock in the intensive care unit (ICU) remains unclear. Studies have found that both excessively high and low BG levels contribute to adverse cardiovascular events. Our study aims to investigate the optimal BG level for critically ill patients with cardiogenic shock and evaluate the effects of optimal BG on the prognosis of patients. Methods: A total of 2013 patients with cardiogenic shock obtained from the Medical Information Mart for Intensive Care (MIMIC) IV database were included in the final cohort for our retrospective observational study for data analysis. The exposure was time-weighted average BG (TWA-BG), which was calculated by the time-series BG records and corresponding time stamps of patients with cardiogenic shock during their stay in the ICU. The cut-off value of TWA-BG was identified by the restricted cubic spline curve and included patients were categorized into three groups: low TWA-BG group (TWA-BG ≤ 104 mg/dl), optimal TWA-BG group (104 < TWA-BG ≤ 138 mg/dl), and high TWA-BG group (TWA-BG > 138 mg/dl). The primary outcome was 28-day mortality, and the secondary outcomes were ICU and in-hospital mortality. We performed the log-rank test to detect whether there is a difference in mortality among different groups in the original cohort. Multiple distinct models were employed to validate the robustness of the results. Results: Our study revealed that the optimal BG level for critically ill patients with cardiogenic shock is 104–138 mg/dl. Compared to the optimal TWA-BG group, the low TWA-BG group (hazard ratio (HR): 1.67, 95% confidence interval (CI): 1.19–2.33, p = 0.002) and high TWA-BG group (HR: 1.72, 95% CI: 1.46–2.03, p < 0.001) exhibited higher 28-day mortality. Similarly, the low TWA-BG group and high TWA-BG group demonstrated higher risks in terms of ICU mortality (low TWA-BG group: HR: 2.30, 95% CI: 1.40–3.79, p < 0.001; high TWA-BG group: HR: 1.77, 95% CI: 1.45–2.17, p < 0.001) and in-hospital mortality (low TWA-BG group: HR: 1.73, 95% CI: 1.19–2.51, p = 0.001; high TWA-BG group: HR: 1.64, 95% CI: 1.38–1.95, p < 0.001). Sensitivity analysis conducted through propensity score matching and the subgroup analysis further substantiated the robustness of the results. Conclusion: The optimal BG level for patients with cardiogenic shock is 104–138 mg/dl. BG levels below 104 mg/dl and above 138 mg/dl were associated with a less favorable prognosis.


  • Open Access

    Identification of Vital Hub Genes and Potential Molecular Pathways of Dermatomyositis by Bioinformatics Analysis

    by Xueren Ouyang, Yuning Zeng, Xiaotao Jiang, Hua Xu, Yile Ning

    Dermatomyositis is an autoimmune disease characterized by severe symmetrical muscle dysfunction and pain. This study was aimed at discovering vital hub genes and potential molecular pathways of DM through bioinformatics analysis, which contributes to identifying potential diagnostic or therapeutic biomarkers and targets. In this study, a total of 915 DEGs in DM samples including 167 upregulated genes and 748 downregulated genes were screened out by the limma package based on the GSE142807 dataset from the Gene Expression Omnibus (GEO) database. Furthermore, the results of Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis indicated that these downregulated genes were highly associated with the immune‐related biological processes and pathways. Therefore, 41 genes closely related to DM were extracted for further study based on the subcluster analysis through the Molecular Complex Detection (MCODE) software plugin in Cytoscape. Ultimately, 10 hub genes (including ISG15, DDX58, IFIT3, CXCL10, and STAT1) were identified as the potential candidate biomarkers and targets. Besides, we found that the identified hub genes directly or indirectly communicated with each other via molecular signaling pathways on the protein and transcription level. In general, under the guidance of bioinformatics analysis, 10 vital hub genes and molecular mechanisms in DM were identified and the expression of proinflammatory factors and interferon family proteins and genes showed high association with DM, which might help provide a theoretical foundation for the development of point‐to‐point targeted therapy in the future treatment of DM.